546 related articles for article (PubMed ID: 25981302)
1. Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy.
Calzetta L; Matera MG; Cazzola M
Eur J Pharmacol; 2015 Aug; 761():168-73. PubMed ID: 25981302
[TBL] [Abstract][Full Text] [Related]
2. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.
Hizawa N
Int J Chron Obstruct Pulmon Dis; 2015; 10():1093-102. PubMed ID: 26089659
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy.
Calzetta L; Matera MG; Cazzola M
Curr Opin Pharmacol; 2018 Jun; 40():95-103. PubMed ID: 29626716
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.
Kardos P; Worsley S; Singh D; Román-Rodríguez M; Newby DE; Müllerová H
Int J Chron Obstruct Pulmon Dis; 2016; 11():2885-2895. PubMed ID: 27932872
[TBL] [Abstract][Full Text] [Related]
5. Overuse of long-acting β
Brunton SA; Hogarth DK
Postgrad Med; 2023 Nov; 135(8):784-802. PubMed ID: 38032494
[TBL] [Abstract][Full Text] [Related]
6. LABA/LAMA fixed-dose combinations
Chen CY; Chen WC; Huang CH; Hsiang YP; Sheu CC; Chen YC; Lin MC; Chu KA; Lee CH; Wei YF
Ther Adv Respir Dis; 2020; 14():1753466620937194. PubMed ID: 32643547
[TBL] [Abstract][Full Text] [Related]
7. Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care.
Punekar YS; Landis SH; Wurst K; Le H
Respir Res; 2015 Nov; 16():141. PubMed ID: 26572740
[TBL] [Abstract][Full Text] [Related]
8. Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update.
Matera MG; Rogliani P; Calzetta L; Cazzola M
Drug Saf; 2016 Jun; 39(6):501-8. PubMed ID: 26924197
[TBL] [Abstract][Full Text] [Related]
9. Dual bronchodilation for the treatment of COPD: From bench to bedside.
Cazzola M; Page C; Rogliani P; Calzetta L; Matera MG
Br J Clin Pharmacol; 2022 Aug; 88(8):3657-3673. PubMed ID: 35514240
[TBL] [Abstract][Full Text] [Related]
10. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
Petite SE
Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
[TBL] [Abstract][Full Text] [Related]
11. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.
Rodrigo GJ; Price D; Anzueto A; Singh D; Altman P; Bader G; Patalano F; Fogel R; Kostikas K
Int J Chron Obstruct Pulmon Dis; 2017; 12():907-922. PubMed ID: 28360514
[TBL] [Abstract][Full Text] [Related]
12. Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review.
Lopez-Campos JL; Calero-Acuña C; Márquez-Martín E; Quintana Gallego E; Carrasco-Hernández L; Abad Arranz M; Ortega Ruiz F
Int J Chron Obstruct Pulmon Dis; 2017; 12():1867-1876. PubMed ID: 28694697
[TBL] [Abstract][Full Text] [Related]
13. The safety of dual bronchodilation on cardiovascular serious adverse events in COPD.
Rogliani P; Ora J; Matera MG; Cazzola M; Calzetta L
Expert Opin Drug Saf; 2018 Jun; 17(6):589-596. PubMed ID: 29716427
[TBL] [Abstract][Full Text] [Related]
14. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β
Skolnik NS; Nguyen TS; Shrestha A; Ray R; Corbridge TC; Brunton SA
Postgrad Med; 2020 Mar; 132(2):198-205. PubMed ID: 31900019
[TBL] [Abstract][Full Text] [Related]
15. Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan.
Yamada H; Hida N; Hizawa N
Int J Chron Obstruct Pulmon Dis; 2018; 13():3141-3147. PubMed ID: 30349222
[TBL] [Abstract][Full Text] [Related]
16. Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life.
Rossi A; Zanardi E; Poletti V; Cazzola M
Int J Chron Obstruct Pulmon Dis; 2015; 10():1383-92. PubMed ID: 26229457
[TBL] [Abstract][Full Text] [Related]
17. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.
Vanfleteren L; Fabbri LM; Papi A; Petruzzelli S; Celli B
Int J Chron Obstruct Pulmon Dis; 2018; 13():3971-3981. PubMed ID: 30587953
[TBL] [Abstract][Full Text] [Related]
18. [Role of bronchodilators in therapy for COPD-mechanisms of LABA and LAMA on airway smooth muscle].
Kume H
Nihon Rinsho; 2016 May; 74(5):813-9. PubMed ID: 27254952
[TBL] [Abstract][Full Text] [Related]
19. Dual LABA/LAMA Therapy versus LABA or LAMA Monotherapy for Chronic Obstructive Pulmonary Disease. A Systematic Review and Meta-analysis in Support of the American Thoracic Society Clinical Practice Guideline.
Mammen MJ; Pai V; Aaron SD; Nici L; Alhazzani W; Alexander PE
Ann Am Thorac Soc; 2020 Sep; 17(9):1133-1143. PubMed ID: 32530702
[No Abstract] [Full Text] [Related]
20. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.
Cazzola M; Molimard M
Pulm Pharmacol Ther; 2010 Aug; 23(4):257-67. PubMed ID: 20381630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
